Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxazepam: update 1989.

F J Ayd1

  • 1West Virginia University Medical Center, Charleston.

International Clinical Psychopharmacology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Oxazepam, an anxiolytic, shows clinical efficacy and may benefit elderly patients. It presents similar risks to other benzodiazepines but potentially lower seizure risk and abuse potential compared to specific alternatives.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent developments in psychiatry of interest to the clergy.

Journal of religion and health·2014
Same author

Dangers in the Use of Some Potent Drugs.

Canadian Medical Association journal·2010
Same author

Legal Liability to Volunteers in Testing New Drugs.

Canadian Medical Association journal·2010
Same author

Physicians and Contraception.

Canadian Medical Association journal·2010
Same author

[Not Available].

Canadian Medical Association journal·2010
Same author

Pertinent medical intelligence: fluoxetine's impact on sexual function.

Maryland medical journal (Baltimore, Md. : 1985)·1995
Same journal

Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.

International clinical psychopharmacology·2026
Same journal

Expanding the horizon of brexpiprazole augmentation in treatment-resistant disorders: from obsessive-compulsive disorder to adolescent bipolar disorder.

International clinical psychopharmacology·2026
Same journal

Acceptability-adjusted speed in psychotic agitation: interpreting pro re nata antipsychotic data in real-world care (commentary on Hatta et al.).

International clinical psychopharmacology·2026
Same journal

Antipsychotics in clinical practice: agitation, polypharmacy, and treatment resistance.

International clinical psychopharmacology·2026
Same journal

Methylphenidate treatment in adults with comorbid attention-deficit/hyperactivity disorder and borderline personality disorder: a prospective longitudinal study.

International clinical psychopharmacology·2026
Same journal

Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026
See all related articles

Area of Science:

  • Pharmacology
  • Clinical Medicine
  • Geriatrics

Background:

  • Oxazepam is a recognized anxiolytic medication.
  • Benzodiazepines are commonly prescribed for anxiety disorders.
  • Patient-specific factors may influence the choice of benzodiazepine.

Purpose of the Study:

  • To evaluate the comparative safety and efficacy profile of oxazepam.
  • To identify potential advantages of oxazepam in specific patient groups, including the elderly.
  • To assess the risks of physiological dependence, seizure induction, and abuse potential associated with oxazepam.

Main Methods:

  • Review of existing clinical data and evidence regarding oxazepam.
  • Comparative analysis of oxazepam against other benzodiazepines (lorazepam, alprazolam, diazepam).

Related Experiment Videos

  • Assessment of reported adverse events, including dependence, seizure risk, and abuse potential.

    • Main Results:

    • Oxazepam demonstrates established clinical efficacy as an anxiolytic.
    • No increased risks were identified for oxazepam compared to other benzodiazepines.
    • Evidence suggests a potentially lower risk of seizure induction than lorazepam and alprazolam.
    • Oxazepam may possess a lower abuse potential when compared to diazepam.

    Conclusions:

    • Oxazepam offers a favorable risk-benefit profile within the benzodiazepine class.
    • Its potential advantages, particularly for the elderly, warrant consideration in clinical practice.
    • Oxazepam represents a potentially safer alternative regarding seizure induction and abuse potential.